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Abstract
Urologic and kidney problems are common in women across their life span and affect their daily life, including
physical activity, sexual relations, social life, and future health. Urological health in women is still understudied
and the underlying mechanisms of female urological dysfunctions are not fully understood. The Society for
Women’s Health Research (SWHR) recognized the need to have a roundtable discussion where researchers
and clinicians would define the current state of knowledge, gaps, and recommendations for future research
directions to transform women’s urological health. This report summarizes the discussions, which focused on
epidemiology, clinical presentation, basic science, prevention strategies, and efficacy of current therapies.
Experts around the table agreed on a set of research, education, and policy recommendations that have the
potential to dramatically increase awareness and improve women’s urological health at all stages of life.
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Introduction
Urologic problems are common in women (Table 1)and they affect their daily life, including physical activity,
sexual relations, social life, and future health.1–3 Multiple
milestones during a woman’s lifetime from infancy to old age
can have an impact on their urological health, but little is
known about urological changes during transition stages.
The Society for Women’s Health Research (SWHR)
convened an interdisciplinary panel of experts (Table 2) to
address the current state of research and to determine the
most pertinent research priorities on October 28–29, 2014, in
Washington, D.C. SWHR has advocated for women’s health
for over two decades through science, policy, and education.
SWHR recognizes the need to have researchers and clinicians
bring their diverse perspectives to define the current state of
research, knowledge gaps, and provide recommendations via
its roundtable meetings.
Seventeen participants were assigned to one of four sub-
groups according to their expertise and research interests
(Table 2). Participants reviewed recent literature to examine
and summarize key urological issues to set a framework for
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the roundtable discussion. A representative from each sub-
topic presented their collective perspectives. In this report,
we summarize the presentations and discussions, including
key knowledge gaps and panel recommendations, for ad-
vancing research on women’s urological health.
Epidemiology and Clinical Presentation
of Urologic Diseases Across the Life Span
Pediatric population
Urological health problems can begin early in childhood.
These problems include increased urinary frequency and ur-
gency (the strong sensation to void that cannot be deferred),
urinary incontinence (UI; defined as involuntary loss of urine)
after toilet training, nocturnal enuresis, urinary tract infections
(UTIs), and bladder and pelvic pain. Children progress to
urinary continence over a period of 5–7 years.4 However, sex
differences in toileting emerge by the age of 5, with girls re-
porting less bedwetting, but more daytime UI, than boys.5
Childhood lower urinary tract symptoms (LUTSs) may be
predictive of adult overactive bladder syndrome (OAB), which
is defined as the uninhibited contraction of the bladder detected
during urodynamics, which results in a constellation of symp-
toms, including urinary urgency with or without incontinence,
urinary frequency, and nocturia.6,7
Comorbid conditions in girls include increased con-
stipation,8 elevated body–mass index (BMI),9,10 forced or
voluntary holding of urine, inadequate water intake, or
consumption of dietary irritants. Stool holding and poor
dietary choices at home and school lead to constipation and
increased fecal loading in children, which is associated
with OAB, UI, UTIs, and bedwetting.8,11 Furthermore,
constipated girls aged 8 to 18 years have significantly
higher obesity rates.12 The relationship of obesity and
constipation with UI and bedwetting is a concern as the
Table 1. Facts on Urologic Conditions in Women
53% of women will have at least one UTI during their lifetime.
24% of women, between the ages of 18–44, have UI.
Greater than 3 million American women are estimated to have IC/PBS.
About 5% of women will have at least one kidney stone by the age of 70.
Bladder cancer is the 10th most prevalent cancer in women, as of 2007.
Renal cell carcinoma is the 8th most common cancer in women, as of 2008.
Direct care for UI in 2000 costs $452.8 million for women (compared with 10.3 million in men).
Twenty-five to 44% women experience recurrent UTI annually.
In every racial group, women are 25–50% as likely as men to develop bladder cancer.
Three percent experience 3 or more recurrent UTIs within 6 months of their initial infection.
Table 2. Society for Women’s Health Research Urologic Health in Women Roundtable
Participant List and Their Affiliations
A. Epidemiology of urologic diseasesa
1. Cara Tannenbaum, MD, Professor, University of Montreal School of Medicine
2. Leslee Subak, MD, Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, Department of
Urology, Department of Epidemiology and Biostatistics, University of California,
San Francisco
3. Roger Dmochowski, MD, Professor, Department of Urology, Vanderbilt University
B. Clinical presentation of urologic diseases
1. Candace Parker-Autry, MD, Assistant Professor, Department of Obstetrics-Gynecology, Wake Forest School of Medicine
2. Clare Close, MD, Pediatric Urology, Close Pediatric Urology
3. Stephanie Kielb, MD, Associate Professor, Department of Urology, Northwestern University
4. George Kuchel, MD, Professor, Department of Geriatrics and Gerontology, University of Connecticut
5. Elizabeth Mueller, MD, Associate Professor, Department of Urology and Obstertics-Gynecology, Loyola University
C. Biological basis of urologic disease
1. Alan J. Wolfe, PhD, Professor, Department of Microbiology and Immunology, Loyola University
2. George Kuchel, MD, Professor, Department of Geriatrics and Gerontology, University of Connecticut
3. Michael DiSanto, PhD, Associate Professor, Department of Urology Research, Cooper Medical School, Rowan
University
4. Toby Chai, MD, Professor, Department of Urology, Yale School of Medicine
5. Margot Damaser, PhD, Professor, Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic
and Louis Stokes Cleveland VA Medical Center
D. Prevention and therapeutic strategies for urologic diseases
1. Matthew Fraser, PhD, Associate Professor, Department of Urology, Duke University
2. James Ashton-Miller, PhD, Professor, Department of Biomechanical Engineering, Department of Internal Medicine,
University of Michigan
3. Margot Damaser, PhD, Professor, Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic
and Louis Stokes Cleveland VA Medical Center
4. Cindy Amundsen, MD, Associate Professor, Department of Urology, Duke University
Participants were assigned to either one or two topic areas and were charged to examine knowledge gaps in their assigned topic area.
aHeidi S. Harvie, MD, MSCE, University of Pennsylvania, Philadelphia, participated in the conference calls before the Roundtable, but
was unable to attend the roundtable meeting.
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effects of these conditions on urologic health in women
during later years are unknown.
Reproductive years
The prevalence of LUTSs in women increases throughout
their reproductive years. Many lifelong behaviors become
established during the teenage and early adult years, which
makes this an ideal time for intervention to prevent poor
bladder and dietary habits that could eventually lead to
LUTSs.5,10,12,13 The most common LUTS at this age is UI,
including stress urinary incontinence (SUI), urgency urinary
incontinence (UUI), and mixed urinary incontinence (MUI).6
SUI is defined as involuntary urine leakage on physical exer-
tion (exercise, coughing, sneezing). UUI is loss of urine with
urgency. Finally, MUI is the occurrence of both SUI and UUI.
UI symptoms may begin early in the reproductive years. In
2011, 41% of young female athletes (median age of 22) re-
ported having at least one episode of SUI during high impact
activities.14,15 Approximately 25% of women under age 40
report SUI during physical activity.16 Of working women
between ages 18–60, 37% reported urine leakage during the
previous 30 days; 44% reported leakage at least once monthly
during work hours; 21% reported weekly incontinence; and
8% reported daily incontinence or more.17 More than 88% of
these women reported a negative impact on concentration,
physical activity levels, self-confidence, and ability to com-
plete their work without requiring interruption.14,15 UI symp-
toms are stigmatizing–90% of women with UI never discuss
their UI symptoms with their healthcare providers.14,15
Pregnancy and vaginal delivery are prevalent comorbid
conditions that may impact UI onset. Most women become
sexually active in their reproductive years and subsequently
experience pregnancy and childbirth, which are known risk
factors for the development of LUTSs. After the first preg-
nancy, the odds of having SUI increased by 2.7-fold; up to a
fourfold increased risk with 5 or more pregnancies.18 During
vaginal delivery, the pelvic floor muscles stretch to accom-
modate passage of the fetus under significant abdominal
pressure. Consequently, innervation and connective tissue
support of the bladder and urethra can be damaged.
While vaginal delivery increased the risk of SUI, cesarean
delivery was not protective against developing UI. In fact, the
risk of developing severe SUI and UUI was equivalent re-
gardless of the mode of birth.19,20 However, age at first de-
livery was associated with risk of UI. Women who delivered
their first baby after the age of 30 had an increased risk of
severe UI later in life and required more surgical interven-
tions than those who delivered when they were younger.21
Postpartum development of UI is experienced by up to
30% of women.22 Pelvic floor muscle exercises done using
repetitions and sets have been shown to decrease incidence
and severity of UI when performed during pregnancy and
after delivery.23,24 However, often UI symptoms recur later
in life as increasing age is the predominant risk factor for
onset of UI symptoms.
Obesity is a common risk factor for LUTSs. Two very large
studies (Nurses Health Study and British Birth Cohort)
showed that women with BMI >30 kg/m2 had a 3.1-fold in-
creased risk of severe UI compared with women with a BMI
<25 kg/m2.25,26 Targeting weight loss in the PRIDE study
showed that an 8% reduction in weight resulted in 47% de-
crease in UI episodes.27 However, the cause–effect relation-
ship between obesity and LUTSs has yet to be well defined.
The role of environmental factors such as diet is growing in
importance in investigations of behavioral modifications for
treatment or prevention of LUTS. In a prospective cohort study
of 7046 community-dwelling women, increased smoking, in-
take of carbonated drinks, and obesity had significant associ-
ations with OAB with urgency incontinence, whereas dietary
intake of vitamin D and calcium was seen as protective.28
Besides obesity and diet, other modifiable risk factors and
comorbidities for UI included smoking, diabetes, constipa-
tion, stroke, hysterectomy, poor overall health, and chronic
obstructive pulmonary disease.29–36 Several of these factors
individually increased the risk of UI by 30%–70%. Medica-
tions that interfere with cerebral processing of bladder
function and/or have cholinergic effects on the smooth
muscles, such as antidepressants, antipsychotic, and sleep
medications, can exacerbate UI.37
Women of reproductive age also have a significant risk of
UTI. The National Ambulatory Care Survey reported almost
30 million physician office visits for UTI from 2002 to 2007
(6-year count), with women over 45 accounting for over 26
million (>87%; 60% over 55 years old) of those visits.38
Hospitalization rates for UTI in women over 65 were 4–45
times higher than for younger women. However, the epide-
miology and treatment of UTIs are complicated due to the
lack of objective diagnostic measures, including variations in
collection (clean catch versus catheterized), lack of routine
cultures to confirm diagnosis, nonspecific symptoms, and
lack of guidelines on the use of antibiotics.
New evidence showed that urine is not sterile, highlighting
our lack of understanding of the roles of asymptomatic versus
symptomatic bacteria.39–51 In addition, the definition of re-
current infections is debatable, further leading to either lack
of appropriate treatment or mistreatment.
The prevalence of bladder pain syndrome (BPS) among
women (3.8%) was as high as other painful conditions, such
as migraine (2.1%), asthma (3.7%), and back pain (4.1%),52
and was much more prevalent in women than men.53 Women
with bladder pain also had chronic pelvic pain. Women with
BPS less than 30 years of age are more likely to experience
urinary urgency, frequency, dysuria, dyspareunia, and pain in
their external genitalia than older women who were more
likely to experience nocturia, UI, and Hunner’s ulcer dis-
ease.54 While we understand the impact BPS has on women,
an improved understanding of the etiology is needed to de-
velop targeted and effective therapies.
Menopause and aging
Menopause is associated with higher risk of recurrent
UTI, UI, LUTSs, and OAB, among other conditions. In ad-
dition, there is limited understanding of whether hormones
affect urological function and, if so, the underlying mecha-
nism(s).55–57 For instance, 70% of women reported onset of
UI at the onset of menopause,55,56 but epidemiological studies
that controlled for age suggested the effect might be driven by
aging and not menopause specifically.
Geriatric population
UI is particularly prevalent in the geriatric population and
has a major impact on quality of life.57,58 Among women over
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age 65, nearly 50% of community-dwelling women, 50% of
female acute care patients, and over 70% of long-term care
patients have UI.59 In a Canadian study, UI increased the sense
of loneliness in seniors from 38% without to 53% with UI.60
Beyond the psychosocial issues, elderly women with UI
are at increased risk for falling and resultant bone fractures
due to increased trips to the bathroom. For example, a self-
reported study of over 6,000 community-dwelling women in the
United States with mean age of 78.5 showed that 55% of
women had fallen within the last 3 years and 8.5% had sus-
tained fractures as a result of their fall.61 Among the women
who fell, 25% had weekly UUI, 19% experienced SUI, and
12% had mixed UI. Urgency (but not stress) UI was found to
be independently associated with falls and fractures, increasing
the risk by 26% and 34%, respectively, likely due to the in-
creased urgency with which women with UI feel the need to get
to the bathroom.61
Underactive bladder (UAB) and incomplete bladder
emptying are associated with aging and are defined by either
a prolonged time to empty the bladder or the inability to void
completely.62 UAB is increasingly being recognized as a
cause of LUTSs, but has been an under-researched area.
Biological Basis of Urologic Diseases in Women
Function and dysfunction of the lower urinary tract
The primary functions of the lower urinary tract (LUT) are
storage of urine (bladder relaxed and urethra contracted),
emptying the bladder (bladder contracts and urethra relaxes),
and protecting the LUT and kidney from damage due to high
pressures or uropathogens. Neural control of LUT function is
complex, involving both autonomic and somatic nervous
systems, central and peripheral nervous systems, autonomous
and volitional control, and is also affected by other psycho-
logical factors such as stress, anxiety, emotion, cognitive
function, and executive function. Normal urinary storage and
bladder emptying rely on proper function and integration of
all these components, as well as pelvic structures supporting
proper LUT position. The mechanisms of integration of all
these factors are not known.
LUT dysfunction can be divided into pathologies of storage
and voiding, which result in incontinence or incomplete emp-
tying, respectively. Pathologies of storage include OAB, SUI,
and UUI, while UAB is a pathology of voiding. OAB can result
from dysfunction of cortical control centers, loss of inhibitory
mechanisms within the detrusor muscle, or other dysfunctions
of the neuromuscular system.63–65 A correlation between in-
flammation and both OAB and interstitial cystitis (IC)/painful
bladder syndrome (PBS) has been reported.66,67 Biomarker
studies may help explain mechanistic etiologies, thereby re-
sulting in novel targets for therapeutic development, or serve to
identify etiology-specific subgroups of symptom-based diag-
noses to enable investigation of them as separate entities.
Among other causes, SUI can result from injury to urethral
nerves, muscles, and connective tissue during childbirth,19,68
a shift in position of the urethra due to insufficient support,69
or loss of elastin and muscle density with aging or excessive
straining or coughing.70
UAB results from a loss of detrusor muscle contractile
power during voiding, decreased neural drive from the brain,
and/or failure of relaxation of the pelvic floor or external
urethral sphincter (EUS), among other etiologies.71,72 Cur-
rently, the mechanistic pathways leading to LUT dysfunction
are not well delineated, thus current therapies treat symp-
toms, but not the biological cause, of dysfunction.
Weakness or damage to the pelvic floor support of the pelvic
organs, including the bladder, can result in a descent of these
organs within the pelvis and in extreme cases through the
pelvis. This condition, pelvic organ prolapse (POP), often oc-
curs together with SUI and fecal incontinence, together col-
lectively known as the female pelvic floor disorders (FPFDs).
Female FPFDs are highly correlated with childbirth, but of-
ten do not occur until years or decades later, suggesting an
interaction with age-related changes. Comorbidities, such as
obesity, chronic cough, and diabetes, are also implicated in
FPFDs.19,73–75
Genetic influences may provide potential explanation of
why some women develop POP without undergoing preg-
nancy or vaginal delivery and other women never get POP,
despite multiple vaginal deliveries.76,77 The mechanisms of
interplay of different contributing factors are not known;
thus, current treatments for FPFDs, particularly POP, are
based primarily on surgical correction of the anatomical
problem and have significant risk of complications.16,78 More
research into causes of FPFDs is required to facilitate de-
velopment of pathophysiology-based therapies, which could
potentially constitute cures rather than symptomatic relief.
Female urinary microbiome
The female bladder contains bacteria that are typically not
cultured by routine clinical laboratory techniques.46,47,51
Preliminary data now suggest that the normal female urinary
flora–the female urinary microbiota (FUM)–may have a role
in modulating the risk of UTI or other urological condi-
tions.39–41,43,45,48,79 One pilot study reported that up to 75%
of women with OAB have detectable bacteria in their urine
and further that different FUM signatures are associated with
OAB.79 Together, these preliminary results may support
FUM signatures as a diagnostic tool to improve treatment
and/or prevent disease by identifying women at risk of LUT
dysfunction48 or by preserving or correcting FUM by pro-
biotic usage.
Effects of aging
The prevalence and incidence of most urological condi-
tions increase with age, but it is unclear whether this is a
causal relationship. While normally the LUT is considered to
be a behavioral system under voluntary control, there is no
perfect correlation of LUT dysfunction with cognitive de-
cline or other comorbidities, suggesting that urological dys-
function is not inevitable with aging.80
Studying the relationship between aging and development
of urological conditions has primarily been done in rodent
animal models. Proper models are key, and simply ovar-
iectomizing young adult animals should not be considered a
model for postmenopausal women, as these models do not
incorporate age-related changes that normally accompany
this event. Thus, when choosing an aging model, it is im-
perative to consider the normal aging process and to avoid
obfuscating an induced pathology with normal aging.
Well-defined knockout animal models that partially mimic
frailty, obesity, diabetes, sarcopenia, and osteoporosis can be
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useful in defining the molecular basis of human disease. For
example, animal models that study the biological pathways
involved in senescence as a consequence of aging have shed
light on the roles of proinflammatory senescent phenotypes,
oxidative stress, telomerase, p53, and mTOR.81 Importantly,
there remains a need for well-characterized genitourinary
tissues from older women and men that could be used to
address primary research questions and human translatability
of animal models as the human diseases that animal re-
searchers attempt to model are still not well defined.
Animal models
Animal models are essential for understanding pathophysi-
ological mechanisms, natural history, and for preclinical testing
of therapeutic approaches, which simply cannot be done in
humans. Animal models of male urologic conditions have been
developed over 70 years; however, animal models for female
urologic conditions have been utilized only for approximately
20 years, and many of these models face significant challenges
because of differences between bi- and quadrupeds.82 There
exist particular needs to develop chronic animal models of
female LUT dysfunction that better represent the multifactorial
spectrum of clinical pathology (i.e., mixed incontinence or
FPFD). Although animal models will never replicate human
diseases perfectly, they can help to dissect individual compo-
nents of disease leading to highly valuable insights into
mechanisms of disease and therapeutic development.
Current advances in genetic manipulation of animals, such
as the CRISPR-cas system, are opening up possibilities to
study humanized animals in ways that were not possible
previously. In addition, genetic studies in humans can be
complemented in animals in such a way that underlying
causes of disease can be identified. For example, heritable
factors may be identified using classical and novel genetic
studies in humans (e.g., GWAS), which can then be mutated
in an animal for confirmation and analysis of the phenotype.
Gaps in our understanding of LUT function
To develop pathophysiologically based therapeutic op-
tions, a better understanding of contributions of the bladder
and the urethra to LUT function is necessary. Historically, the
approach has been to study the function of the entire LUT and
to attribute changes in function as the result of changes in
bladder function without considering the contribution of
urethral function. While this is problematic for understanding
both compartments of the LUT, studies that have been de-
signed to study each compartment in isolation have focused
disproportionately on bladder function. For example, the
mechanisms that allow the female urethra to be functionally
competent are not well studied, leading to an insufficient
understanding of the pathophysiologies that underlie outlet
obstruction and SUI in women. Therefore, more research
should be directed to urethral function.
Another major gap in basic knowledge is bladder sensory
signaling. Recent studies suggest that the primary cause of
LUTSs may be due to alterations in sensory processing, in-
cluding disorders in the brain.83 In addition, the urothelium
that lines the bladder lumen has been suggested to act not
only as a barrier but also as a sensory transducer of bladder
filling, but the mechanisms of this putative role require fur-
ther elucidation. Nonetheless, the bladder mucosa and the
lamina propria have been suggested to be important func-
tional centers of the bladder.84 The protective role of estrogen
on the urothelium against UTIs and bladder cancer has been
suggested, but is not fully understood,85,86 similar to the role
of reproductive hormones in LUT function and dysfunction.
Much research has been devoted to understanding the
regulation of contraction and relaxation of the detrusor or
urethral smooth muscle by direct neural regulation.87 By
understanding the intracellular mechanisms of smooth mus-
cle contraction and regulation, we will improve our under-
standing of the excitation–contraction coupling event to
develop new targets for novel therapeutic options.
Clinically, research on women who can void, despite not
being able to generate sufficient detrusor contraction pressures,
is of interest because it opens the possibility of more than one
mechanism involved in voiding. Last, research is being con-
ducted to develop alternatives to catheters for those patients
who cannot void/empty their bladder, including bladder re-
training, pharmacologic treatment, and neuromodulation.88
Prevention and Therapeutic Strategies
for LUT Dysfunction
The last two decades have brought advances in treatments
and therapies for female LUT dysfunction. However, im-
provement in therapies and development of prevention strat-
egies require further research. A lack of precise delineation of
pathophysiologic etiologies often leads to improper therapy
selection with poor results. A precise understanding of eti-
ologies will lead to effective prevention strategies.
Behavioral therapies
Behavioral therapies include behavior modification, bladder
retraining, education, and self-help strategies. Reducing weight
and increasing muscle tone improve continence and reduce the
risk of LUTSs.25,89,90 Management of fluid and caffeine intake,
reduction of constipation, and training the bladder to hold
longer (i.e., bladder retraining) also have significant effects on
incontinence.64,90 Smoking cessation and proper treatment of
chronic obstructive pulmonary disease (COPD) to reduce
stress induced by coughing also reduce urine leakage.31,91
Last, several medications can affect urological conditions.
Sleeping aids can interfere with the signaling between the
bladder and brain, resulting in leakage.92 Behavioral modifi-
cations targeted at urological and gynecological hygiene (e.g.,
postcoital voiding) may reduce the risk of UTI.93,94
Pelvic floor muscle training
Multiple studies have shown that women who used pelvic
floor muscle training (PFMT) were 8 times more likely to
report improvement in continence compared with controls.95
A drawback and perhaps the reason for hesitation on the part
of the public is that PFMT and other behavioral changes take
time and effort–as many as 16 weeks for initial improve-
ments–and a lifelong commitment to exercise. In addition,
ineffective self-management can result in lack of improve-
ment and frustration.96 Therapies and prevention technologies
that provide feedback (i.e., biofeedback) can help women
understand whether they are doing PFMT correctly.96 Meta-
analyses across more than 100 randomized control trials
found inconsistent effects of almost all other therapies com-
pared with PFMT.78,97
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Passive devices: pessaries and urethral inserts
Vaginal pessaries have been used successfully to help reduce
SUI.92 Many women choose to use these devices because they
can decide when they need to use them. For example, an athlete
might decide to use her pessary while she participates in her
athletic event, when her symptoms are acute, but remove the
pessary for the rest of her daily life. Other intraurethral and
intravaginal devices are popular and effective at strengthening
the pelvic floor, thereby aiding continence.90,92 These include
weighted vaginal cones, vaginal spheres, and urethral inserts
(e.g., Femsoft).98 Clinical studies show that the use of these
devices in combination with proper counseling and training
was far more effective than their use alone.90
Pharmacologic treatments
Many pharmacological options exist for treating UUI and
OAB, including anticholinergic (antimuscarinic) agents such
as oxybutynin, tolterodine, trospium chloride, darifenacin,
solifenacin, and ER fesoterodine.99 These agents inhibit de-
trusor overactivity and may inhibit voiding ability. Antic-
holinergic agents are usually used in patients who do not
improve with other more conservative treatments because of
their side effects and the relatively high discontinuation
rates.99 b3-adrenergic agonists are a newer class of drugs,
which act at the level of myogenic detrusor reflex (instead of
the neurogenic reflex), inhibiting not only detrusor contrac-
tions but may also interfere with filling.99 Onabotuli-
numtoxinA (Botox) inhibits involuntary contractions of the
detrusor and therefore leads to improved continence.90
More than 70% of patients report at least a 50% reduction
in symptoms after treatment, suggesting that Botox is rela-
tively effective.92 However, there remain questions regarding
the length and durability of the treatment, as well as the
location of administration (i.e., trigone vs. outside the tri-
gone). Last, with Botox there remain questions about how
much damage the toxin has on muscles, whether the toxin
accumulates over the life span, or whether multiple concur-
rent uses (cosmetic and urologic, for instance) can have long-
lasting effects that have not yet been observed.
Table 3. Proposed Research Recommendations from SWHR’s Urology Roundtable
Topic Specific recommendation
Basic and
Translational
Science
Develop better animal models to study urologic health and disease across a woman’s life span:
To better reflect the coexisting diseases and outcomes as seen in patients
Capture risk factors
Identify clinical phenotypes and predictive biomarkers that allow for preclinical model development
to define causes and treatment of disease
To use in preclinical testing of novel therapeutics and prevention strategies
Determine role of urinary microbiome in
Normal bladder function throughout a woman’s life span
Cause and effects of disease states
Future diagnostic tools and therapies
Determine cellular and molecular mechanisms and genetic influences across a woman’s life span to
Understand lower urinary tract health in normal and disease states
Establish impact of lifetime events or disease comorbidities on lower urinary tract function.
Define disease subtypes for LUTSs.
Improve knowledge of human lower urinary tract physiology to
Develop better ways to clarify sensory and motor function in the urethra and bladder
Understand the central neurological control of lower urinary tract
Understand the role of cross talk between pelvic viscera
Determine the role of biological sex in lower urinary tract health and disease in
Host response to microbes
Protection against carcinogenesis
Determining sex differences in terms of contribution from urethral muscles toward urethral closure
and the relative contributions of vascular, smooth, and striated muscles to urethral closure across the
life span
Develop ways to improve individual acceptance to lifestyle changes that have been shown to promote
bladder health
Develop prevention strategies for LUTSs
Develop diagnostic markers for specific pathophysiology of LUTSs
Clinical Increase the participation of women with multiple comorbidities in clinical trials, including the elderly
and minorities
Establish biobanks of tissues, blood, and urine across a woman’s life span
Explore novel therapies such as cell therapy and regenerative medicine
Therapies Develop rational therapeutic approaches for LUTSs based on subtypes and biomarkers (personalized
medicine)
Examine differential response to same therapies by different people
Examine synergistic effects of combination therapies
Examine better ways to improve adherence to existing therapies
Based on existing knowledge gaps in the urology field, the discussions at the roundtable meeting led to the identification of key
recommendations listed below.
LUTSs, lower urinary tract symptoms; SWHR, Society for Women’s Health Research.
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There are currently very few or no pharmacological
treatments for SUI or UAB. For example, bethanechol is a
muscarinic agonist used to treat UAB,72 but there is no level 1
evidence for the use of this agent. Because of this, treatment
of UAB is primarily limited to bladder catheterization. SUI
can be treated with a-adrenergic agonists (pseudoephedrine,
phenylpropanolamine) that contract the bladder neck or
SNRI antidepressants (duloxetine) that act centrally on the
pudendal motor neuron, which contracts the EUS.100 These
agents may have serious side effects and should be consid-
ered carefully in a risk–benefit analysis.100
A number of options exist for treatment of IC/PBS, in-
cluding oral pentosan polysulfate, which presumably restores
the glycosaminoglycan layer, which has been described to be
a protective layer over the apical urothelial cell. Anti-
histamines have also been used to prevent mast cell degran-
ulation.101,102 Antidepressants and opioid pain medicines are
also administered to reduce the symptoms of IC/PBS.102
Neuromodulation
Neuromodulation of the sacral 3rd (S3) nerve can modulate
the urinary reflex to benefit patients with UUI and idiopathic
urinary retention. The precise mechanisms of action for S3
nerve stimulation are not understood. For example, it is thought
that increased S3 (pudendal nerve) afferent activity blocks
abnormal descending excitatory, promicturition reflexes that
occur in patients with UUI.88 However, S3 stimulation can also
suppress an exaggerated guarding reflex in patients with uri-
nary retention.88 Proper understanding of the mechanism of
therapeutic action of S3 could help identify patient subgroups
who would respond better to different therapies. Irrespective of
the method of action, neuromodulation is recommended as a
third-line therapy.
The clinical data are not clear on the persistent effects of
sacral nerve stimulation and suggest that there is only a short
period during which the effects continue.88 However, long-
term effects are not understood, and whether neuromodula-
tion results in neuroplasticity is not known. Current im-
provements in electric leads and generators make S3 more
appealing to patients. Broader and longer randomized control
trials are needed to understand how frequently, for how long,
and whether booster sessions of neuromodulation are needed
for effective long-term treatment. Additional basic research
is needed to understand the exact mechanism of action. Ad-
ditional research into other nerves, such as the dorsogenital
and pudendal nerves, is also needed to develop as therapies
for patients with LUTS.
Surgery for stress UI
Midurethral slings are the most commonly performed sur-
geries for SUI, resulting in improvement in SUI symptoms in
more than 70% of subjects.103 The midurethral sling is the most
studied procedure for SUI, and many studies have shown du-
rability, efficacy, and improvement of quality of life.104 Al-
though uncommon, when mesh complications such as urinary
tract erosion occur or when chronic pain develops, these side
effects can be difficult to manage.
Regenerative medicine
Urethral bulking is a minimally invasive option for women
with SUI. However, treatments are not long lasting and need
to be repeated periodically.78 Regenerative medicine, which
uses adult stem cells to repair and/or regenerate tissues and
organs, may provide a more durable solution. Several clinical
trials are showing improved outcomes with stem cells injected
into the bladder or urethra of women with SUI.105 Stem cells
are thought to repair damaged tissue by differentiation and
proliferation. They also secrete bioactive factors that induce
innate repair mechanisms, suggesting application of regenera-
tive pharmacotherapy for SUI.105
Electrostimulation therapies that seem to regenerate tissue
damaged during childbirth are also currently being explored
as a prevention strategy for UI.106 While still in the early
stages, regenerative medicine offers opportunities to improve
treatment and to prevent further development of disease
conditions.
Discussion and Recommendations
After a day of topical presentations and discussions, the
entire group discussed the most important research recom-
mendations emerging from the Roundtable. A summary of
Table 4. Proposed Education and Policy Recommendations from SWHR’s Urology Roundtable
Topic Specific recommendations
Education Implement professional development for primary and secondary school educators regarding bladder health
Promote urinary health education and outreach in schools with community partner engagement
Increase cross talk between clinicians and basic scientists
Increase patient literacy, knowledge, and engagement on urinary and pelvic floor health
Educate medical students, primary care physicians, primary nurse practitioners, and pediatricians on urinary
health
Develop educational campaign tools for lay public on healthy bladder habit
Collaborate with subspecialty groups in advocacy
Policy Promote evidence-based guidelines in women’s urologic health
Encourage insurance companies and Center for Medicare and Medicaid Services to reimburse for behavioral
therapies for LUTS
Develop a US-based public toilet map, maybe as an app if nonexistent, in conjunction with green spaces
Mandate building code changes to make more washrooms for women in all buildings in the United States
Develop workplace recommendations to facilitate healthy bladder behavior
Modify primary and secondary school schedules to allow healthy bladder behavior
Increase availability and accessibility to public restrooms
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the discussion specific to each area follows. The specific
recommendations are listed in Table 3.
As a whole, the experts agreed that given the demonstrated
effectiveness of incontinence treatment, research is needed
on methods of increasing healthcare-seeking behavior for
women with incontinence as well as implementation of
successful prevention and treatment strategies that extend the
reach of and optimize individual adherence to effective
continence promotion programs. However, while many ef-
fective treatments are available, there exists a fundamental
lack of understanding of pathophysiology underlying LUT
dysfunction, resulting in nontargeted therapies. Physicians
are only able to treat symptoms, but cannot correct patho-
physiological causes. This shortcoming is combined with the
generalized grouping of patients according to symptoms ra-
ther than disease mechanisms and results in relatively poor
management and ineffective treatment.
Discussions concluded that it is important to understand
normal function along with dysfunction to identify the root
cause of a problem with the ultimate goal of preventing
disease. Knowledge gaps in research have resulted from in-
adequate phenotype definitions of urinary dysfunction, in-
sufficient data to determine what is normal and abnormal, and
animal models that do not appropriately reflect human dis-
ease. Specific research recommendations address these lim-
itations, including the need for clinicians to better define
disease states so that animal models that more accurately
reflect these human conditions and their etiology can be de-
veloped.
There is a need for better understanding of molecular,
cellular, microbiome, and physiological mechanisms of
normal and abnormal function and improved understanding
of the role of biological sex in urological function. Additional
work is needed to develop animal models that discriminate
between different disease etiologies (in incontinence, for
example) to properly assess the efficacy and safety of newly
developed treatments. Last, a precise understanding of etio-
logic mechanisms can inform how to develop preventative
treatment strategies in the future.
The expert panel also discussed emerging issues that
(while not related to research) are equally important. These
fell into either public education/outreach or policy/advocacy
categories (Table 4). The recommendations are meant for a
general audience, including researchers, clinicians, advocacy
groups, and policy makers. Experts around the table agreed
that not enough awareness exists about the real impact of
urological conditions on women’s health and that there is a
need to disseminate this information to a wide range of au-
diences. Dissemination of information to women patients
and their healthcare providers and insurance companies is
needed to increase urological health literacy and greater
adoption and reimbursement of prevention strategies. Key
audiences are primary and secondary school educators, nurses,
and administrators given the fact that so many of our bladder
habits are established in the early years.
Practical evidence-based information for lay audiences
such as location of public toilets or workplace recommen-
dations that promote bladder health by increasing number/
location of available toilets or building time for toilet breaks
during work shifts can also have significant impact on im-
proving women’s health at large. The group also identified an
opportunity for more collaboration across disciplines and
with advocacy groups to develop evidence-based guidelines
in women’s urological health that could ultimately become
part of every woman’s health management.
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